drug
panitumumab
Marketedupdated 6mo agoby $AMGN AMGEN INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying panitumumab
- phase1A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
- phase2A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- phase2A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- phase1Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal Cancer
- phase2Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
- phase3Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- phase1A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- phase1A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that